Interestingly, we were able to show that a fusion protein can decrease the tumour burden in some, although not all mice. These data are consistent

with previous studies in clinical treatment of tumours found in the peritoneum showing the benefit of the IL-2 but also heterogeneity in the effects of treatment.51 The reason for this heterogeneity is not known, although it might reflect differences in the relative balance of effector cells and regulatory T cells.52 There is a great deal of interest in manipulating the immune response at specific sites exploiting the biological activity of cytokines. One innovative approach takes advantage of monoclonal antibodies to tumour-associated antigens (e.g. anti-HER-2/neu or anti-ganglioside GD2) that may have anti-tumour activities themselves, and genetically fuses them to cytokines (e.g. IL-2 or IL-12), which are then expressed and infused Lapatinib chemical structure in vivo.53–55 Although the antibody fused to the cytokine diffuses throughout the recipient, it eventually accumulates at the tumour site as a result of antibody binding and retention so the cytokine concentration increases at tumour sites. This approach differs fundamentally

from the one presented in selleck chemical the current work. In the current study the antibody does not bind the tumour but rather serves to inhibit the cytokine. The cytokine in the anti-tumour-associated antigen–antibody fusion is constitutively active and so may have unwanted effects. In contrast, in the approach demonstrated here, the cytokine activity is attenuated because of the specific binding component and increases only when activated by proteases. Another interesting strategy employs the latency-associated protein (LAP) of transforming growth factor-β (TGF-β) that is genetically fused to interferon-β (IFN-β) via a cleavable linker

recognized by an MMP such that the IFN-β becomes more active when the linker is cleaved. In this method, unlike the specific inhibition presented here, the LAP protein sterically shields the IFN-β from its receptor. This approach has been used to down-regulate inflammatory responses in a mouse model of arthritis.56 A variety of cytokines have been tested for their ability to act as adjuvants in the context of anti-tumour responses. Interestingly, while some studies found that immunization with irradiated Urease or mitomycin-treated transfected tumour cells expressing IL-2 can aid in initiating anti-tumour responses,57,58 other studies showed more modest effects.59 In contrast, viable tumour cells expressing even relatively low amounts of IL-2 within the tumour microenvironment can have dramatic immune effects and even result in tumour rejection.17,58,60,61 It is therefore likely that IL-2 produced by transfected growing tumours at the tumour site is largely acting locally, probably by enhancing T-cell and NK cell responses at the tumour site.